Form 4 for ABBV AbbVie
Accepted 2025-04-02 00:00:00 ET · period of report 2025-03-31 · accession 0001415889-25-009687 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-02 | 2025-03-31 | ABBV | Stewart Jeffrey Ryan | EVP, Chief COMMERCIAL Off | M - OptEx | $79.02 | +25.7K | 112.1K | +30% | +$2.03M |
| DM | 2025-04-02 | 2025-03-31 | ABBV | Stewart Jeffrey Ryan | EVP, Chief COMMERCIAL Off | S - Sale+OE | $210.08 | -58.8K | 86.4K | -41% | -$12.36M |
| D | 2025-04-02 | 2025-03-31 | ABBV | Stewart Jeffrey Ryan | EVP, Chief COMMERCIAL Off | M - OptEx | $79.02 | -25.7K | 0 | -100% | -$2.03M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 par value | 2025-03-31 | M | A | 25,700 | $79.02 | 112,066 | D | — | — | |
| 2 | Common | Common Stock, $0.01 par value | 2025-03-31 | S | D | 33,132 | $210.54 | 53,234 | D | — | — | (F2) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.54 to $210.63, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock, $0.01 par value | 2025-03-31 | S | D | 25,700 | $209.49 | 86,366 | D | — | — | (F1) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.43 to $209.60, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Derivative | Option (Right to Buy) | 2025-03-31 | M | D | 25,700 | $79.02 | 0 | D | $79.02 · — to 2029-02-20 | 25,700 Common Stock | (F4) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |